Psychiatric Annals

Feature 

Integrating Therapies for Anxiety Disorders

Michael Hollifield, MD; Amanda Mackey, MD; Jonathan Davidson, MD

Abstract

Anxiety disorders are among the most prevalent mental disorders in the general population of the United States. As a group, anxiety disorders share many clinicopathological features, which allow clinicians to use similar diagnostic and treatment principles for each of them. More than 200 studies have examined treatment efficacy for anxiety disorders. This article provides background on common features, reviews the efficacy of monotherapy and combined treatment, and discusses principles and goals of evaluation and treatment that target common features.

ABOUT THE AUTHORS

Dr. Hollifield is associate professor, Psychiatry and Family and Geriatric Medicine, and director, Anxiety Disorders Program, University of Louisville, Louisville, KY. Dr. Mackey is senior resident, Psychiatry and Behavioral Sciences, University of Louisville. Dr. Davidson is professor, Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC.

Address reprint requests to: Michael Hollifield, MD, University of Louisville, Med Center One, 501 E. Broadway, Louisville, KY 40202; or e-mail: m.hollifield@louisville.edu.

Dr. Davidson receives grant or research support from Pfizer, Lilly, GlaxoSmithKline, Wyeth, UCB Pharma, and Forest, serves as a consultant and scientific advisor to Pfizer, Lilly, GlaxoSmithKline, and Forest, and serves on the Speakers’ Bureau for Pfizer, GlaxoSmithKline, and Forest. Drs. Hollifield and Mackey disclosed no relevant financial relationships.

Abstract

Anxiety disorders are among the most prevalent mental disorders in the general population of the United States. As a group, anxiety disorders share many clinicopathological features, which allow clinicians to use similar diagnostic and treatment principles for each of them. More than 200 studies have examined treatment efficacy for anxiety disorders. This article provides background on common features, reviews the efficacy of monotherapy and combined treatment, and discusses principles and goals of evaluation and treatment that target common features.

ABOUT THE AUTHORS

Dr. Hollifield is associate professor, Psychiatry and Family and Geriatric Medicine, and director, Anxiety Disorders Program, University of Louisville, Louisville, KY. Dr. Mackey is senior resident, Psychiatry and Behavioral Sciences, University of Louisville. Dr. Davidson is professor, Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC.

Address reprint requests to: Michael Hollifield, MD, University of Louisville, Med Center One, 501 E. Broadway, Louisville, KY 40202; or e-mail: m.hollifield@louisville.edu.

Dr. Davidson receives grant or research support from Pfizer, Lilly, GlaxoSmithKline, Wyeth, UCB Pharma, and Forest, serves as a consultant and scientific advisor to Pfizer, Lilly, GlaxoSmithKline, and Forest, and serves on the Speakers’ Bureau for Pfizer, GlaxoSmithKline, and Forest. Drs. Hollifield and Mackey disclosed no relevant financial relationships.

Anxiety disorders are among the most prevalent mental disorders in the general population of the United States. As a group, anxiety disorders share many clinicopathological features, which allow clinicians to use similar diagnostic and treatment principles for each of them. More than 200 studies have examined treatment efficacy for anxiety disorders. This article provides background on common features, reviews the efficacy of monotherapy and combined treatment, and discusses principles and goals of evaluation and treatment that target common features.

ABOUT THE AUTHORS

Dr. Hollifield is associate professor, Psychiatry and Family and Geriatric Medicine, and director, Anxiety Disorders Program, University of Louisville, Louisville, KY. Dr. Mackey is senior resident, Psychiatry and Behavioral Sciences, University of Louisville. Dr. Davidson is professor, Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC.

Address reprint requests to: Michael Hollifield, MD, University of Louisville, Med Center One, 501 E. Broadway, Louisville, KY 40202; or e-mail: m.hollifield@louisville.edu.

Dr. Davidson receives grant or research support from Pfizer, Lilly, GlaxoSmithKline, Wyeth, UCB Pharma, and Forest, serves as a consultant and scientific advisor to Pfizer, Lilly, GlaxoSmithKline, and Forest, and serves on the Speakers’ Bureau for Pfizer, GlaxoSmithKline, and Forest. Drs. Hollifield and Mackey disclosed no relevant financial relationships.

10.3928/00485713-20060501-03

Sign up to receive

Journal E-contents